Alteogen Signs License Agreement Worth 823 Billion Won with Biogen for SC Formulation Drug Development
Alteogen announced on March 25 that it has signed an exclusive license agreement with the global pharmaceutical company Biogen for the development and commercialization of subcutaneous (SC) formulation biopharmaceuticals based on ALT-B4, which utilizes its Hybrozyme technology.
Under this agreement, Biogen will secure exclusive rights to develop and commercialize subcutaneous formulations of two biopharmaceutical products using Alteogen's ALT-B4.
Upon signing the contract, Alteogen will receive an upfront payment of 20 million dollars (approximately 30 billion won), and an additional upfront payment of 10 million dollars (approximately 15 billion won) when the development of the second product is initiated. The company may also receive up to 549 million dollars (approximately 823 billion won) in milestone payments associated with the development, approval, and sales of the two products, and will be entitled to royalties based on product sales after commercialization. According to the terms of the agreement, Biogen will also have the option to develop a third product.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Tae Yeon Jeon, CEO of Alteogen, stated, “Biogen is a leading global biotechnology company with strong research and development capabilities. We are very pleased to pursue the development of innovative products for patients together through this partnership.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.